Drug · DIN 02269007
TARCEVA
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since October 1, 2024; first marketed January 5, 2007.
- Drug Identification Number (DIN)
- 02269007
- Company (DIN owner)
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Erlotinib L01EB02
- Class
- Human
- Record last updated
- June 15, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ERLOTINIB (ERLOTINIB HYDROCHLORIDE) | 25 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 7, 2005: NOC 7211New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “tarceva”. A notice may cover another product or only some lots: read it to see what it covers.
- TARCEVA (erlotinib) - Use in Maintenance Treatment for PatientsJanuary 21, 2016 · Drugs · Product safety
- Archived - Association of TARCEVA (erlotinib) with cases of gastrointestinal perforation, Stevens-Johnson syndrome, and corneal perforation - For the PublicMay 11, 2009 · Drugs
- Association of TARCEVA (erlotinib) with cases of gastrointestinal perforation, Stevens-Johnson syndrome, and corneal perforation - For Health ProfessionalsMay 11, 2009 · Drugs
- Archived - The use of Tarceva (erlotinib) in patients with moderate hepatic impairment and advanced solid tumours - For the PublicDecember 17, 2008 · Drugs
- The use of Tarceva (erlotinib) in patients with moderate hepatic impairment and advanced solid tumours - For Health ProfessionalsDecember 17, 2008 · Drugs
Other DINs named TARCEVA
- DIN 02269015 · Cancelled Post Market
- DIN 02269023 · Cancelled Post Market